Igg1 isotype control antibody

Manufactured by Leinco Technologies

The IgG1 isotype control antibody is a laboratory reagent used in flow cytometry and other immunoassays. It serves as a negative control to establish the background signal and to differentiate specific from non-specific binding.

Automatically generated - may contain errors

Lab products found in correlation

Anti ly6g, by BioXCell (1 mentions) Igg2a isotype control antibody, by Leinco Technologies (1 mentions) Anti ly6c, by BioXCell (1 mentions)

2 protocols using igg1 isotype control antibody

Cytokine Administration and Immune Cell Depletion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice received the indicated doses of mrIL-13 (0.5 µg/dose; BioLegend), mrIFN-γ (1.5 µg/dose; BioLegend), or 10⁴ or 2.5 × 10⁵ IUs of mrIFN-β or mrIFN-αA (PBL Assay Science, Piscataway, NJ) by i.t instillation. Antibody depletions were performed as stated for each experiment. For anti-IFNAR1 blocking treatment (7 (link), 66 (link)), we used the following antibodies: 1.5 mg of anti-IFNAR1 (MAR1-5A3) monoclonal antibody (MAb) or IgG1 isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.p. For IFN-α/IFN-β treatment (67 (link)), we used 0.25 mg of anti-IFN-α (RMMA-1) MAb/anti-IFN-β (RMMB-1) MAb or an IgG1 isotype control antibody (~95 and ~90% efficacy, respectively; PBL Assay Science, Piscataway, NJ) administered i.p. For anti-IFNAR1/Ly6G treatment, we used 1.75 mg of anti-IFNAR1 (MAR1-5A3) MAb or IgG1 isotype control antibody (Leinco Technologies; St. Louis, MO) administered i.p. and 0.25 mg of anti-Ly6G (1A8; average ~90% depletion) MAb or IgG2a isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.t. For anti-Ly6C/Ly6G depletion treatment, we used 0.25 mg anti-Ly6G (1A8; average ~97% depletion) or 0.25 mg anti-Ly6C (both from Bio X Cell, West Lebanon, NH) MAb or IgG2a isotype control antibody (Leinco Technologies, St. Louis, MO) administered i.t. (see Fig. S7 in the supplemental material).

Shepardson K.M., Larson K., Morton R.V., Prigge J.R., Schmidt E.E., Huber V.C, & Rynda-Apple A. (2016). Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. mBio, 7(3), e00506-16.

+ Open protocol

+ Expand

Type I IFN and IFN-γ Blockade in LCMV

Check if the same lab product or an alternative is used in the 5 most similar protocols

For type I IFN blockade, WT or Stat3^fl/flCd4^cre(Stat3^−/−) mice were treated at day -1 with 600 μg of MAR1-5A3 IFNαβR blocking antibody or IgG1 isotype control antibody (both from Leinco Technologies) in PBS via i.p. injection (Sheehan et al., 2006 (link)), before infection with LCMV Armstrong at day 0. For IFN-γ blockade, WT mice were treated at day 0 and day 3 post LCMV Armstrong infection with 250 μg of XMG1.2 IFN-γ blocking antibody or PBS vehicle control (Abrams et al., 1992 (link)). IL-2 blocking antibody (JES6-1A12) was used in vitro at a concentration of 10 μg/mL (Abrams et al., 1992 (link)).

Ray J.P., Marshall H.D., Laidlaw B.J., Staron M.M., Kaech S.M, & Craft J. (2014). The Transcription Factor STAT3 and Type I Interferons Are Mutually Repressive Insulators for Differentiation of Follicular Helper and T Helper_1 Cells. Immunity, 40(3), 367-377.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!